In June 2013, the Company concluded a collaboration agreement with Cytokinetics, Inc. of the U.S., focusing on the research, development and commercialization of skel- etal muscle activators. The primary objective of the collabo- ration is to advance novel therapies for diseases and medical conditions associated with muscle weakness. The two parties will jointly conduct research and development in the area of skeletal muscle activation. 

In March 2013, the Company exercised its right to terminate the worldwide license agreement with Ambit Biosciences Corporation of the U.S. concluded in 2009 for the joint development and commercialization of FLT3 kinase inhibitors including quizartinib (generic name/code name: AC220). The agreement, which the Company exer- cised its right to terminate for strategic reasons, came to an end on September 3, 2013. 

In October 2013, the Company entered into an exclusive collaboration agreement with Mitokyne, Inc. of the U.S. for joint research and development in the area of mitochondria- related diseases. Under the agreement, the two companies are jointly conducting research and development to find breakthrough treatments in this therapeutic area, in which an effective therapy is yet to be established. 

In December 2013, the Company entered into a joint research agreement with Immuno-Biological Laboratories Co., Ltd. regarding pharmaceutical applications of recom- binant human proteins made using transgenic silkworms. Under the agreement, the two companies are jointly con- ducting research and development with respect to a useful recombinant human protein made using transgenic silk- worms. This includes examining and evaluating the produc- tion method and looking into the possibility of developing the protein as medicine. 

In January 2014, the Company entered into an agree- ment for a strategic alliance with ClearPath Development Company (“ClearPath”) of the U.S. to form a portfolio of vaccines targeting infectious diseases. Through this  alliance, the Company will fund the development of a  virosome vaccine technology for respiratory syncytial virus, licensed from Mymetics Corporation of the U.S., by RSV Corporation, a company managed and operated by ClearPath. The alliance will help the Company to build up its vaccine portfolio. 

In February 2014, the Company exercised its right to 

terminate a license agreement it entered into in 2011 with AVEO Pharmaceuticals, Inc. (“AVEO”) of the U.S. for the development and commercialization of tivozanib (generic name/development code: ASP4130), an inhibitor of all three vascular endothelial growth factor receptors 1, 2 and 3, which had been under joint development. The Company took the decision for strategic reasons, based on the clini- cal status of the three indications studied (renal cell carci- noma, colorectal cancer and breast cancer). The termination of the license agreement will be effective August 11, 2014, at which time tivozanib rights will be returned to AVEO. 

Also in February 2014, the Company amended a license agreement, which was entered into in February 2010, on isavuconazole (generic name), an azole antifungal agent under joint development with Basilea Pharmaceutica Ltd. of Switzerland, for strategic reasons. Based on the amend- ment, the territories subject to the license agreement have been changed from “worldwide except Japan” to “the U.S. and Canada,” and the Company is now responsible for applications for approval and has exclusive full respon- sibility for the manufacture and sale of isavuconazole in both countries. 

In March 2014, the Company entered into a collabora- tion agreement with Daiichi Sankyo Company, Limited to form a compound library sharing partnership for approxi- mately 400,000 selected compounds from the whole library of each company. The collaboration enables each party to promote innovative new medicine research and development. 

## Commercial Partnerships and Measures to Strengthen Business Capabilities 

In August 2013, the Company and MSD K.K. entered into a co-promotion agreement in Japan for Suglat. Under the agreement, the manufacture and sale of the drug will be carried out by the Company, while the Company, MSD, and Kotobuki Pharmaceutical Co., Ltd. will co-promote it. 

In July 2013, the Company established a sales affiliate in Singapore, Astellas Pharma Singapore Pte. Ltd. The business started operations in October 2013. Astellas Pharma Singapore will mainly commercialize Astellas’ global products through its own sales force in Singapore and supervise the sales of such products through a Contract 

